Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to the world health organization classification

Oncology Letters

Volumn 1, Issue 1, 2010, Pages 155-159

  Masui, Toshihiko ^a   Doi, Ryuichiro ^a   Ito, Tatsuo ^a   Kami, Kazuhiro ^a   Ogawa, Kohei ^a   Harada, Daisuke ^a   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Fluorodeoxyglucose positron emission tomography; Pancreatic endocrine neoplasm; World health organization classification

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN;

ADULT; ARTICLE; BENIGN TUMOR; CANCER GRADING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISTANT METASTASIS; DRUG UPTAKE; FEMALE; GASTRINOMA; GLUCAGONOMA; HISTOLOGY; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULINOMA; INTERMETHOD COMPARISON; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PROGNOSIS; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

EID: 77955763053     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000029     Document Type: Article

References (20)

1. Rha SE, Jung SE, Lee KH, Ku YM, Byun JYand Lee JM: CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur JRadiol 62: 371-377, 2007.
2. Modlin IM and Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer 79: 813-829, 1997.
3. Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA and Cameron JL: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 2: 472-482, 1998.
4. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF and Klimstra DS: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20: 2633-2642, 2002.
5. Heitz PU, Komminoth P, Perren A, Klimstra DS, Dayal Y, Bordi C, Lechagon J, Centeno BA and Kloppel G: Tumours of the endocrine pancreas. In: Pathology and Genetics of Tumours of Endocrine Organs (World Health Organization Classification of Tumours). DeLellis RA, Lloyd RV, Heitz PUand Eng C (eds). IARC Press, Lyon, pp177-182, 2004.
6. Capella C, Heitz PU, Hofler H, Solcia E and Kloppel G: Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 55: 11-23, 1994.
7. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A and Falconi M: Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 19: 903-908, 2008.
8. Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM, Moch H, Heitz PU, Kloeppel G, Komminoth P and Perren A: WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 31: 1677-1682, 2007.
9. Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, Klimstra DS and Allen PJ: Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25: 5609-5615, 2007.
10. Reske SN and Kotzerke J: FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, 'Onko-PET III', 21 July and 19 September 2000. Eur J Nucl Med 28: 1707-1723, 2001.
11. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R, Mortelmans L and Reske SN: FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30: BP115-BP124, 2003.
12. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH and Hor G: Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25: 79-83, 1998.
13. Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, Ferlin G and Pedrazzoli S: Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22: 588-592, 1998.
14. Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K and Langstrom B: Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 44: 68-76, 2000.
15. Eriksson B, Bergstrom M, Sundin A, Juhlin C, Orlefors H, Oberg K and Langstrom B: The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann NY Acad Sci 970: 159-169, 2002.
16. Pawlikowski M and Melen-Mucha G: Somatostatin analogs from new molecules to new applications. Curr Opin Pharmacol 4: 608-613, 2004.
17. Pacak K, Eisenhofer G and Goldstein DS: Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 25: 568-580, 2004.
18. Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G and Pedrazzoli S: 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 7: 953-959, 2003.
19. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, Mortelmans LA and Demedts MG: Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17: 3201-3206, 1999.
20. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S and Rusch V: Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22: 3255-3260, 2004.